Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Eli Lilly and Company currently has a 0.7% dividend yield. As of November 7, 2024, Gilead Sciences, Inc. had a $114.2 billion market cap, putting it in the 98th percentile of all stocks. Gilead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

Wells Fargo raised the firm’s price target on Gilead (GILD) to $105 from $100 and keeps an Overweight rating on the shares. The firm ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (SNSE:GILD) from Buy to Hold. There are 2,850 funds or institutions reporting positions in Gilead ...